Dr Nicholas Madden

• The CRISMA (Clinical Research, Investigation, and
• Systems Modeling of Acute Illness) Laboratory,
• Department of Critical Care Medicine,
• University of Pittsburgh,
• Pittsburgh, PA,
• USA

Obtaining the correct diagnosis often requires a detailed family medical history gastritis diet ��� cheap generic esomeprazole uk, lipid analyses in family members gastritis symptoms in spanish discount esomeprazole 40 mg line, and sometimes specialized testing gastritis or gallbladder esomeprazole 20 mg purchase on line. These individuals usually do not have a Mendelian disorder but instead are genetically predisposed and have secondary factors (diet gastritis diet virus order esomeprazole us, obesity gastritis diet cheese buy esomeprazole 20 mg amex, glucose intolerance, alcohol ingestion, estrogen therapy) that contribute to the hyperlipidemia. At present, there is no compelling reason to perform molecular studies to further refine the molecular diagnosis because the clinical management is not affected. Patients with more moderate hypercholesterolemia that does not segregate in families as a monogenic trait are likely to have polygenic hypercholesterolemia. Combined Hyperlipidemia the most common errors in the diagnosis of lipid disorders involve patients with combined hyperlipidemia. Once the hyperlipidemia is accurately classified, efforts should be directed to rule out any possible secondary causes of the hyperlipidemia (Table 421-4). Hypothyroidism should be ruled out by measuring serum thyroid-stimulating hormone. Patients who drink alcohol should be encouraged to decrease or preferably eliminate their intake. Dietary fat intake should be restricted to reduce the formation of chylomicrons in the intestine. Pharmacologic Therapy for Severe Hypertriglyceridemia Despite the above interventions, however, many patients with severe hypertriglyceridemia require pharmacologic therapy (Table 421-5). There are three classes of drugs that are used for management of these patients: fibrates, omega-3 fatty acids (fish oils), and niacin. Fibrates are generally well tolerated, but are associated with an increase in the incidence of gallstones. Fibrates can cause myopathy, especially when combined with other lipid-lowering therapy (statins, niacin), and can raise creatinine. Importantly, fibrates can potentiate the effect of warfarin and certain oral hypoglycemic agents, so the anticoagulation status and plasma glucose levels should be closely monitored in patients on these agents. Fish oils are a reasonable consideration for firstline therapy in patients with severe hypertriglyceridemia (>500 mg/ dL) to prevent pancreatitis. In general, fish oils are well tolerated, with the major side effect being dyspepsia. They appear to be safe, at least at doses up to 3­4 g, but can be associated with a prolongation in the bleeding time. Because it has a number of side effects and can be difficult to use, it is at best a third-line agent for the management of severe hypertriglyceridemia. Niacin therapy is generally started at lower doses and gradually titrated up to higher doses. Niacin can cause dyspepsia and can exacerbate esophageal reflux and peptic ulcer disease. Mild elevations in transaminases occur in up to 15% of patients treated with any form of niacin. Niacin can raise plasma levels of uric acid and precipitate gouty attacks in susceptible patients. Thus, it is imperative that patients with hypercholesterolemia be assessed for cardiovascular risk and for the need for intervention. Lifestyle the first approach to a patient with hypercholesterolemia and high cardiovascular risk is to make any necessary lifestyle changes. In obese patients, efforts should be made to reduce body weight to the ideal level. Patients should receive dietary counseling to reduce the content of saturated fats, trans fats, and cholesterol in the diet. Substantial (greater than three times the upper limit of normal) elevation in transaminases is relatively rare, and mild-to-moderate (one to three times normal) elevation in transaminases in the absence of symptoms need not mandate discontinuing the medication. Meta-analyses of large randomized controlled clinical trials with statins do not suggest an increase in any major noncardiac diseases except type 2 diabetes. A small excess percentage of those taking statins will develop diabetes but the benefits associated with the reduction in cardiovascular events outweigh the increase in incidence of diabetes. The only roles for ezetimibe in monotherapy are in patients who do not tolerate statins and in sitosterolemia. Bile acid SeQueStrantS (reSinS) Bile acid sequestrants bind bile acids in the intestine and promote their excretion rather than reabsorption in the ileum. To maintain the bile acid pool size, the liver diverts cholesterol to bile acid synthesis. Therefore, patients with hypertriglyceridemia generally should not be treated with bile acid­binding resins. Because bile acid sequestrants are not systemically absorbed, they are very safe and the cholesterol-lowering drug of choice in children and in women of childbearing age who are lactating, pregnant, or could become pregnant. They are effective in combination with statins and in combination with ezetimibe and are particularly useful with one or both of these drugs for patients with severe hypercholesterolemia or those with statin intolerance. Due to their mechanism of action, each drug causes an increase in hepatic fat, the long-term consequences of which are unknown. In addition, lomitapide is associated with gastrointestinalrelated side effects, and mipomersen is associated with skin reactions and flu-like symptoms. These differences in populations are reflected in the range of waist circumferences considered to confer risk in different geographic locations (Table 422-1). The prevalence of the metabolic syndrome varies around the world, in part reflecting the age and ethnicity of the populations studied and the diagnostic criteria applied. In the United States, the metabolic syndrome is less common among African-American men and more common among Mexican-American women. In France, studies of a cohort of 30- to 60-year-olds have shown a <10% prevalence for each sex, although 17. Greater global industrialization is associated with rising rates of obesity, which are expected to increase the prevalence of the metabolic syndrome dramatically, especially as the population ages. Moreover, the rising prevalence and severity of obesity among children is reflected in features of the metabolic syndrome in a younger population. Increases in waist circumference predominate among women, whereas increases in fasting plasma triglyceride levels. However, despite the importance of obesity, patients who are of normal weight may also be insulin resistant and may have the metabolic syndrome. Compared with individuals who watch television or videos or use the computer <1 h daily, those who do so for >4 h daily have a twofold increased risk of the metabolic syndrome. It is estimated that the great majority (~75%) of patients with type 2 diabetes or impaired glucose tolerance have the metabolic syndrome. Evolution of the criteria for the metabolic syndrome since the original definition by the World Health Organization in 1998 reflects growing clinical evidence and analysis by a variety of consensus conferences and professional organizations. For participants whose designation was "other race-including multiracial," thresholds that were once based on Europid cutoffs (94 cm for men and 80 cm for women) and on South Asian cutoffs (90 cm for men and 80 cm for women) were used. For participants who were considered "other Hispanic," the International Diabetes Federation thresholds for ethnic South and Central Americans were used. Cardiovascular Disease Individuals with the metabolic syndrome are twice as likely to die of cardiovascular disease as those who do not, and their risk of an acute myocardial infarction or stroke is threefold higher. The onset of insulin resistance is heralded by postprandial hyperinsulinemia, which is followed by fasting hyperinsulinemia and ultimately by hyperglycemia. Plasma albumin-bound free fatty acids are derived predominantly from adipose-tissue triglyceride stores released by intracellular lipolytic enzymes. Fatty acids are also derived from the lipolysis of triglyceriderich lipoproteins in tissues by lipoprotein lipase. Insulin mediates both antilipolysis and the stimulation of lipoprotein lipase in adipose tissue. Fatty acids impair insulin-mediated glucose uptake and accumulate as triglycerides in both skeletal and cardiac muscle, whereas increased glucose production and triglyceride accumulation take place in the liver. Leptin resistance has also been raised as a possible pathophysiologic mechanism to explain the metabolic syndrome. Physiologically, leptin reduces appetite, promotes energy expenditure, and enhances insulin sensitivity. In addition, leptin may regulate cardiac and vascular function through a nitric oxide­dependent mechanism. The oxidative stress hypothesis provides a unifying theory for aging and the predisposition to the metabolic syndrome. In studies of insulinresistant individuals with obesity or type 2 diabetes, the offspring of patients with type 2 diabetes, and the elderly, a defect in mitochondrial oxidative phosphorylation that leads to the accumulation of triglycerides and related lipid molecules in muscle has been identified. Recently, the gut microbiome has emerged as an important contributor to the development of obesity and related metabolic disorders, including the metabolic syndrome. Both of these lipoprotein changes may contribute to atherogenic risk in patients with the metabolic syndrome. With increases in visceral adipose tissue, adipose tissue­derived free fatty acids are directed to the liver. It is also possible that visceral fat is a marker for-but not the source of-excess postprandial free fatty acids in obesity. The effect of insulin on this process is complex, but hypertriglyceridemia is an Glucose Intolerance (See also Chap. The relationship between impaired fasting glucose or impaired glucose tolerance and insulin resistance is well supported by studies of humans, nonhuman primates, and rodents. To compensate for defects in insulin action, insulin secretion and/or clearance must be modified so that euglycemia is sustained. Ultimately, this compensatory mechanism fails, usually because of defects in insulin secretion, resulting in progression from impaired fasting glucose and/ or impaired glucose tolerance to diabetes mellitus. Paradoxically, under normal physiologic conditions, insulin is a vasodilator with secondary effects on sodium reabsorption in the kidney. Insulin also increases the activity of the sympathetic nervous system, an effect that may be preserved in the setting of insulin resistance. Insulin resistance is characterized by pathwayspecific impairment in phosphatidylinositol-3-kinase signaling. In the endothelium, this impairment may cause an imbalance between the production of nitric oxide and the secretion of endothelin 1, with a consequent decrease in blood flow. Although these mechanisms are provocative, evaluation of insulin action by measurement of fasting insulin levels or by homeostasis model assessment shows that insulin 2452 resistance contributes only partially to the increased prevalence of hypertension in the metabolic syndrome. Another possible mechanism underlying hypertension in the metabolic syndrome is the vasoactive role of perivascular adipose tissue. Other paracrine effects could be mediated by leptin or other proinflammatory cytokines released from adipose tissue, such as tumor necrosis factor. Hyperuricemia is another consequence of insulin resistance and is commonly observed in the metabolic syndrome. There is growing evidence not only that uric acid is associated with hypertension but also that reduction of uric acid normalizes blood pressure in hyperuricemic adolescents with hypertension. The mechanism appears to be related to an adverse effect of uric acid on nitric acid synthase in the macula densa of the kidney and stimulation of the renin-angiotensin aldosterone system. Proinflammatory Cytokines the increases in proinflammatory cytokines-including interleukins 1, 6, and 18; resistin; tumor necrosis factor; and the systemic biomarker C-reactive protein-reflect overproduction by the expanded adipose tissue mass. Adipose tissue­derived macrophages may be the primary source of proinflammatory cytokines locally and in the systemic circulation. It remains unclear, however, how much of the insulin resistance is caused by the paracrine effects of these cytokines and how much by the endocrine effects. The relative contributions of adiponectin deficiency and overabundance of the proinflammatory cytokines are unclear. On physical examination, waist circumference may be expanded and blood pressure elevated. The presence of either or both of these signs should prompt the clinician to search for other biochemical abnormalities that may be associated with the metabolic syndrome. Because these physical findings characteristically are associated with severe insulin resistance, other components of the metabolic syndrome should be expected. However, in nonalcoholic steatohepatitis, triglyceride accumulation and inflammation coexist. Nonalcoholic steatohepatitis is now present in 3­12% of the population of the United States and other Western countries. Of patients with the metabolic syndrome, ~25­60% have nonalcoholic fatty liver disease and up to 35% have nonalcoholic steatohepatitis. As the prevalence of overweight/obesity and the metabolic syndrome increases, nonalcoholic steatohepatitis may become one of the more common causes of end-stage liver disease and hepatocellular carcinoma. An increase in asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, also relates to endothelial dysfunction. In addition, microalbuminuria may be caused by altered endothelial pathophysiology in the insulin-resistant state. Women with polycystic ovary syndrome are two to four times more likely to have the metabolic syndrome than are women without polycystic ovary syndrome. With these associations, it is not surprising that individuals with obstructive sleep apnea frequently have the metabolic syndrome. Moreover, when biomarkers of insulin resistance are compared between patients with obstructive sleep apnea and weight-matched controls, insulin resistance is found to be more severe in those with apnea. Continuous positive airway pressure treatment improves insulin sensitivity in patients with obstructive sleep apnea. The medical history should include evaluation of symptoms for obstructive sleep apnea in all patients and polycystic ovary syndrome in premenopausal women. Laboratory Tests Measurement of fasting lipids and glucose is needed in determining whether the metabolic syndrome is present.

The pons and deep cerebral white matter are typical locations gastritis diet ginger purchase generic esomeprazole canada, and these capillary malformations can be seen in patients with hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber) syndrome gastritis diet ������� 20 mg esomeprazole buy with visa. Cavernous angiomas are typically <1 cm in diameter and are often associated with a venous anomaly gastritis diet ��� buy esomeprazole 20 mg visa. Surgical resection eliminates bleeding risk and may reduce seizure risk gastritis diet for children 20 mg esomeprazole buy mastercard, but it is usually reserved for those malformations that form near the brain surface gastritis juicing recipes discount esomeprazole 20 mg fast delivery. Dural arteriovenous fistulas are acquired connections usually from a dural artery to a dural sinus. Patients may complain of a pulse-synchronous cephalic bruit ("pulsatile tinnitus") and headache. Fistulas have been observed to appear months to years following venous sinus thrombosis, suggesting that angiogenesis factors elaborated from the thrombotic process may cause these anomalous connections to form. Alternatively, dural arteriovenous fistulas can produce venous sinus occlusion over time, perhaps from the high pressure and high flow through a venous structure. Raskin the general principles around headache as a cardinal symptom are covered elsewhere (Chap. The most common are migraine, tension-type headache, and the trigeminal autonomic cephalalgias, notably cluster headache; the complete list is summarized in Table 447-1. It is usually an episodic headache associated with certain features such as sensitivity to light, sound, or movement; nausea and vomiting often accompany the headache. A useful description of migraine is a recurring syndrome of headache associated with other symptoms of neurologic dysfunction in varying admixtures (Table 447-2). The brain of the migraineur is particularly sensitive to environmental and sensory stimuli; migraine-prone patients do not habituate easily to sensory stimuli. Headache can be initiated or amplified by various triggers, including glare, bright lights, sounds, or other afferent stimulation; hunger; let-down from stress; physical exertion; stormy weather or barometric pressure changes; hormonal fluctuations during menses; lack of or excess sleep; and alcohol or other chemical stimulation, such as with nitrates. Pathogenesis the sensory sensitivity that is characteristic of migraine is probably due to dysfunction of monoaminergic sensory control systems located in the brainstem and hypothalamus. Centrally, the second-order trigeminal neurons cross the midline and project to ventrobasal and posterior nuclei of the thalamus for further processing. Additionally, there are projections to the periaqueductal gray and hypothalamus, from which reciprocal descending systems have established antinociceptive effects. Other brainstem regions likely to be involved in descending modulation of trigeminal pain include the nucleus locus coeruleus in the pons and the rostroventromedial medulla. Triptans arrest nerve signaling in the nociceptive pathways of the trigeminovascular system, at least in the trigeminal nucleus caudalis and trigeminal sensory thalamus, in addition to cranial vasoconstriction, while ditans, now shown conclusively to be effective in acute migraine, act only at neural targets. An interesting range of neural targets is now being actively pursed for the acute and preventive management of migraine. Moreover, there is dopamine receptor hypersensitivity in migraineurs, as demonstrated by the induction of yawning, nausea, vomiting, hypotension, and other symptoms of a migraine attack by dopaminergic agonists at doses that do not affect nonmigraineurs. Dopamine receptor antagonists are effective therapeutic agents in migraine, especially when given parenterally or concurrently with other antimigraine agents. These neurons in turn project in the quintothalamic tract and, after decussating in the brainstem, synapse on neurons in the thalamus. Important modulation of the trigeminovascular nociceptive input comes from the dorsal raphe nucleus, locus coeruleus, and nucleus raphe magnus. Diagnosis and Clinical Features Diagnostic criteria for migraine headache are listed in Table 447-3. A high index of suspicion is required to diagnose migraine: the migraine aura, consisting of visual disturbances with flashing lights or zigzag lines moving across the visual field or of other neurologic symptoms, is reported in only 20­25% of patients. Patients with episodes of migraine that occur daily or near-daily are considered to have chronic migraine (see "Chronic Daily Headache" in Chap. Migraine must be differentiated from tension-type headache (discussed below), the most common primary headache syndrome seen in the population. Migraine has several forms that have been defined (Table 447-1): migraine with and without aura and chronic migraine, the latter occurring 15 days or more a month, as the most important. Migraine at its most basic level is headache with associated features, and tension-type headache is headache that is featureless. Vertigo can be prominent; it has been estimated that one-third of patients referred for vertigo or dizziness have a primary diagnosis of migraine. Migraine aura can have prominent brainstem symptoms, and the terms basilar artery and basilar-type migraine have now been replaced by migraine with brainstem aura (Table 447-1). Hypothalamic, dorsal midbrain, and dorsolateral pontine activation is seen in triggered attacks in the premonitory phase before pain, whereas in migraine attacks, dorsolateral pontine activation persists, as it does in chronic migraine (not shown). The dorsolateral pontine area, which includes the noradrenergic locus coeruleus, is fundamental to the expression of migraine. Moreover, lateralization of changes in this region of the brainstem correlates with lateralization of the head pain in hemicranial migraine; the scans shown in panels C and D are of patients with acute migraine headache on the right and left side, respectively. Posterior hypothalamic gray matter activation by positron emission tomography in a patient with acute cluster headache. High-resolution T1-weighted magnetic resonance image obtained using voxel-based morphometry demonstrates increased gray matter activity, lateralized to the side of pain in a patient with cluster headache. It is helpful for patients to understand that migraine is an inherited tendency to headache; that migraine can be modified and controlled by lifestyle adjustments and medications, but it cannot be eradicated; and that, except in some occasions in women on oral estrogens or contraceptives, migraine is not associated with serious or life-threatening illnesses. Most patients benefit by the identification and avoidance of specific headache triggers. A regulated lifestyle is helpful, including a healthy diet, regular exercise, regular sleep patterns, avoidance of excess caffeine and alcohol, and avoidance of acute changes in stress levels, being particularly wary of the let-down effect. The measures that benefit a given individual should be used routinely because they provide a simple, cost-effective approach to migraine management. Patients with migraine do not encounter more stress than headache-free individuals; over-responsiveness to changes in stress appears to be the issue. If these measures fail to prevent an attack, pharmacologic approaches are then needed to abort an attack. The selection of the optimal regimen for a given patient depends on a number of factors, the most important of which is the severity of the attack. Mild migraine attacks can usually be managed by oral agents; the average efficacy rate is 50­70%. In general, an adequate dose of whichever agent is chosen should be used as soon as possible after the onset of an attack. If additional medication is required within 60 min because symptoms return or have not abated, the initial dose should be increased for subsequent attacks or a different class of drug tried as first-line treatment. Migraine therapy must be individualized; a standard approach for all patients is not possible. A therapeutic regimen may need to be constantly refined until one is identified that provides the patient with rapid, complete, and consistent relief with minimal side effects (Table 447-5). However, the effectiveness of these agents in migraine is usually less than optimal in moderate or severe migraine attacks. The combination of acetaminophen, aspirin, and caffeine has been approved for use by the U. The combination of aspirin and metoclopramide has been shown to be comparable to a single dose of oral sumatriptan. Ergotamine and dihydroergotamine are nonselective receptor Source: Adapted from the International Headache Society Classification (Headache Classification Committee of the International Headache Society, 2013). On how many days in the last 3 months did you miss work or school because of your headaches How many days in the last 3 months was your productivity at work or school reduced by half or more because of your headaches (do not include days you counted in question 1 where you missed work or school). On how many days in the last 3 months did you not do household work because of your headaches How many days in the last 3 months was your productivity in household work reduced by half or more because of your headaches (do not include days you counted in question 3 where you did not do household work). On how many days in the last 3 months did you miss family, social, or leisure activities because of your headaches Because the clinical studies demonstrating the efficacy of ergotamine in migraine predated the clinical trial methodologies used with the triptans, it is difficult to assess the clinical efficacy of ergotamine versus the triptans. In general, ergotamine appears to have a much higher incidence of nausea than triptans but less headache recurrence. Nasal Nasal formulations of dihydroergotamine (Migranal), zolmitriptan (Zomig nasal), or sumatriptan can be useful in patients requiring a nonoral route of administration. Although in theory nasal sprays might provide faster and more effective relief of a migraine attack than oral formulations, their reported efficacy is only approximately 50­60%. Studies with a new inhalational formulation of dihydroergotamine indicate that its absorption problems can be overcome to produce rapid onset of action with good tolerability. Drug absorption is impaired during migraine because of reduced gastrointestinal motility. Delayed absorption occurs even in the absence of nausea and is related to the severity of the attack and not its duration. Each drug in the triptan class has similar pharmacologic properties but varies slightly in terms of clinical efficacy. Rizatriptan and eletriptan are the most efficacious of the triptans currently available in the United States. Sumatriptan and zolmitriptan have similar rates of efficacy as well as time to onset, with an advantage of having multiple formulations, whereas almotriptan has a similar rate of efficacy to sumatriptan and is better tolerated, and frovatriptan and naratriptan are somewhat slower in onset and are better tolerated. Clinical efficacy appears to be related more to the tmax (time to peak plasma level) than to the potency, half-life, or bioavailability. This observation is consistent with a large body of data indicating that fasteracting analgesics are more effective than slower-acting agents. Triptans are generally not effective in migraine with aura unless given after the aura is completed and the headache initiated. Recurrence of headache, within usual time course of an attack, is another important limitation of triptan use and occurs at least occasionally in most patients. A nonnauseating dose of ergotamine should be sought because a dose that provokes nausea is too high and may intensify head pain. This condition is likely not a separate headache entity but a reaction of the migraine patient to a particular medicine. Migraine patients who have two or more headache days a week should be cautioned about frequent analgesic use (see "Chronic Daily Headache" in Chap. In general, a preventive medication should be considered in the subset of patients with four or more attacks a month. Significant side effects are associated with the use of many of these agents; furthermore, determination of dose can be difficult because the recommended doses have been derived for conditions other than migraine. The mechanism of action of these drugs is unclear; it seems likely that the brain sensitivity that underlies migraine is modified. Patients are usually started on a low dose of a chosen treatment; the dose is then gradually increased, up to a reasonable maximum, to achieve clinical benefit. Drugs must be taken daily, and there is usually a lag of between 2 to 12 weeks before an effect is seen. This group includes amitriptyline, nortriptyline, flunarizine, phenelzine, gabapentin, and cyproheptadine. Placebo-controlled trials of onabotulinum toxin type A in episodic migraine were negative, whereas, overall, placebo-controlled trials in chronic migraine were positive. Phenelzine and methysergide are usually reserved for recalcitrant cases because of their serious potential side effects. Methysergide may cause retroperitoneal or cardiac valvular fibrosis when it is used for >6 months, and thus monitoring is required for patients using this drug; the risk of fibrosis is about 1:1500 and is likely to reverse after the drug is stopped. Many patients are managed adequately with low-dose amitriptyline, propranolol, candesartan, topiramate, or valproate. If these agents fail or lead to unacceptable side effects, second-line agents such as methysergide or phenelzine can be used. Once effective stabilization is achieved, the drug is continued for ~6 months and then slowly tapered to assess the continued need. Many patients are able to discontinue medication and experience fewer and milder attacks for long periods, suggesting that these drugs may alter the natural history of migraine. The pain typically builds slowly, fluctuates in severity, and may persist more or less continuously for many days. Because the clinical studies demonstrating the efficacy of this combination analgesic in migraine predated the clinical trial methodologies used with the triptans, it is difficult to compare the efficacy of this sympathomimetic compound to other agents. Nasal A nasal preparation of butorphanol is available for the treatment of acute pain. As with all opioids, the use of nasal butorphanol has little role in migraine treatment. Opioids do not treat the underlying headache mechanism; rather, they act to alter the pain sensation, and there is evidence their use may decrease the likelihood of a response to triptans in the future. Moreover, in patients taking oral opioids, such as oxycodone or hydrocodone, habituation or addiction can greatly confuse the treatment of migraine. The name tension-type headache implies that pain is a product of nervous tension, but there is no clear evidence for tension as an etiology. Because of the associated nasal congestion or rhinorrhea, patients are often misdiagnosed with "sinus headache" and treated with decongestants, which are ineffective. The cycling pattern and length, frequency, and timing of attacks are useful in classifying patients. Cluster Headache Cluster headache is a relatively rare form of primary headache with a population frequency of approximately 0. The pain is deep, usually retroorbital, often excruciating in intensity, nonfluctuating, and explosive in quality. At least one of the daily attacks of pain recurs at about the same hour each day for the duration of a cluster bout. The typical cluster headache patient has daily bouts of one to two attacks of Commonly used preventives are listed with typical doses and common side effects. Food and Drug Administration; local regulations and guidelines should be consulted. Cluster headache is characterized as chronic when there is less than 1 month of sustained remission without treatment. Onset is nocturnal in about 50% of patients, and men are affected three times more often than women. Patients with cluster headache tend to move about during attacks, pacing, rocking, or rubbing their head for relief; some may even become aggressive during attacks. This is in sharp contrast to patients with migraine, who prefer to remain motionless during attacks.

40 mg esomeprazole purchase mastercard. Limpieza intestinal (detox kit) ♡ Bella All Natural.

Isoleucine (Branched-Chain Amino Acids). Esomeprazole.

• What other names is Branched-chain Amino Acids known by?
• How does Branched-chain Amino Acids work?
• Reducing muscle breakdown during exercise.
• Reducing loss of appetite and improving nutrition in elderly patients on hemodialysis.
• Enhancing exercise or athletic performance.
• What is Branched-chain Amino Acids?

Source: http://www.rxlist.com/script/main/art.asp?articlekey=96966

The more common peripheral dysgraphias affect letter form generation and are analogous to dysarthria or dysphonia in speech where the rate gastritis or gallbladder buy 40 mg esomeprazole, rhythm gastritis symptoms in pregnancy purchase esomeprazole 40 mg visa, force chronic gastritis raw food esomeprazole 40 mg otc, or amplitude of the writing movements are affected gastritis symptoms patient.co.uk buy 20 mg esomeprazole amex. Neurological diseases of the pyramidal gastritis diet 100 esomeprazole 20 mg purchase without a prescription, extrapyramidal or cerebellar systems can all cause this type of peripheral dysgraphia. Case History I Peripheral alexia: Hemianopic alexia this case demonstrates, in a single subject, how text reading speed depends on the degree of visual sparing there is to the right of fixation in left-to-right readers. The patient, a 48 year old righthanded male, was found to have a right-sided visual field defect. He had a macular splitting hemianopia in his (dominant) right eye, and a macular sparing hemianopia (with 3-4° of foveal/parafoveal sparing) in his left eye. Distance is on the y-axis with the left of the stimulus at top and right at bottom. Fixations (horizontal portions of the trace) lasting between 150 and 350 ms are interrupted by saccades (vertical portions) lasting ~20 ms. The start of the first fixation onto the first the central dysgraphias Central dysgraphias are more common than peripheral dysgraphias and are usually seen in association with other language internalmedicinebook. Regressive saccades occur in both traces (open arrowheads) but the patient clearly takes longer (12 secs as opposed to 9. How Children Learn to Read: Current Issues and New Directions in the Integration of Cognition, Neurobiology and Genetics of Reading and Dyslexia Research and Practice. Mini-Mental State- Practical Method for Grading Cognitive State of Patients for Clinician. Reading disorders in primary progressive aphasia: A behavioral and neuroimaging study. Unlocking the nature of the phonologicaldeep dyslexia continuum: the keys to reading aloud are in phonology and semantics. Rehabilitation of hemianopic alexia in patients with postgeniculate visual field disorders. Rehabilitation of hemianopic dyslexia: are words necessary for re-learning oculomotor control Adaptation of eye-movements to simulated hemianopia in reading and visual exploration: Transfer or specificity Untersuchungen über die Lokalisation der Functionen in der Grosshirnrinde des Menschen. Optokinetic therapy improves text reading in patients with hemianopic alexia: a controlled trial. The relationship between visual crowding and letter confusability: Towards an understanding of dyslexia in 44. Cummings Emotional and behavioural dysfunction frequently accompany cognitive impairment1­3 and dementia. Recognizing neuropsychiatric syndromes requires particular patience and thoughtfulness in cognitively disturbed patients, who may be less able to help identify symptoms. Its scoring system rates the frequency and severity of 12 neuropsychiatric abnormalities that can be grouped into clusters of co-occurring symptoms (Table 19. Agitation/aggression (hyperactive cluster) Clinical phenomenology and importance Of the hyperactive symptoms, agitation and aggression are the most serious and the most likely to require clinical attention. In part, this is because other hyperactive symptoms may go unreported unless they are accompanied by agitation or aggression. In addition, agitation and aggression are almost always accompanied by one or more of the other hyperactive symptoms. Agitation is an inappropriate and disruptive increase in activity, and may manifest as motoric (pacing, fidgeting, picking), verbal/vocal (shouting, cursing, grunting), or affective (anger, laughing, crying) symptoms. Nevertheless, assessment of agitation by clinicians and caregivers has demonstrated intra- and inter-test reliability. Therefore, a cognitively impaired individual who appears agitated must be assessed for underlying causes, which may be physical. Although a careful evaluation will sometimes reveal a secondary cause for these behaviours, agitation can be a primary symptom of cognitive disease. This may include promised, threatened, or actual physical assault, property damage, or unwanted sexual activity. Among dementia patients, aggressive behaviours have been associated with depressive symptoms, male gender, and worse cognition. Neurobiology the neurobiology of agitation and aggression in dementia is not well understood. There are probably multiple underlying causes for these behaviours, further influenced by disease type and stage, underlying psychiatric history, psychosocial circumstances, and other variables. Because many of these studies included patients with psychotic symptoms, specific details about the use of antipsychotics are discussed in the section on management of psychotic symptoms, below. Depression and apathy (mood cluster) Clinical phenomenology and importance Most studies estimate the prevalence of major depression episodes in dementia to be between 20 per cent and 40 per cent, rates twice as high as those seen in the cognitively intact population, with even more patients suffering minor or subsyndromal depression,23,87­89 rates twice as high as those seen in the cognitively intact population. Alternately, mood symptoms could be the first signs of intrusions of dementia pathology that will later produce impaired cognition. The underpinnings of the relationship between depression and dementia-like most of what we have learned about each of these illnesses-are likely to be complex. Patients with dementia usually have some degradation of recognition, recollection, and/or communication of emotional states and neurovegetative symptoms (see Box 19. The patient who claims he sleeps well should be asked what time he falls asleep, when he gets up for the day, and whether he feels refreshed in the mornings. In addition, agitation, Treatment There are few controlled studies of treatments specifically for agitation/aggression in dementia, and these treatments have been largely unsuccessful. A large controlled study of citalopram 30 mg daily demonstrated an advantage over placebo in reducing some measures of agitation and caregiver distress at nine weeks. In addition to sad mood, behavioural changes included insomnia, poor appetite, depressed affect (including tearfulness during the examination), disinterest in spending time with her family, and lack of energy. The family noted that she had stopped going for daily walks and did not want to attend her weekly card game. She was diagnosed with major depressive disorder and antidepressant medication was prescribed. When the patient returned three months later, her family reported partial resolution of the depression symptoms. The medical provider educated the family and patient about dementia-related apathy, which all agreed was likely affecting this patient. The patient and family declined, citing their reluctance to change the treatment regimen in the face of her recent improvement. They decided instead to pursue behavioural management-making a daily schedule of activities for the patient to follow, suggesting that she participate in activities (as opposed to asking whether she wanted to do them), visiting more frequently, and moving recreational supplies (television, bookshelf, radio) from her bedroom to the living room. They reported that although the patient still did not generate her own ideas about how to spend her day, her level of activity increased considerably over the next few months. Anxiety frequently accompanies depression but can also be present in non-depressed individuals. Like depression, anxiety impacts negatively on quality of life and creates caregiver distress, even at early stages of cognitive disturbance. However, there is much less evidence supporting differences in monamine activity between depressed and non-depressed dementia patients. She attempted to demonstrate these marks to the examiner, who was unable to see the lesions to which she referred. However, she had stopped gardening and attending a twice-weekly senior breakfast because she spent much of the day catching up on sleep. The patient did not see her concern about the animal as a medical problem, and did not want antipsychotic medication to reduce her preoccupation and anxiety about the animal. They accepted trazodone, which did help the patient sleep better at night, but she discontinued it because of excessive daytime drowsiness. Her sleep and daytime activities eventually returned to normal, and she continued putting out milk for the animal. These are more likely to cause side-effects in demented patients, and should be used for dementia-related depression only after failures of less problematic drugs, if at all. The results of studies evaluating treatments for apathy have been inadequate,129,147 as most have measured apathy as a secondary or post hoc outcome. This evidence, from trials in a large number of patients, supports the use of cholinesterase inhibitors at typical treatment doses. The overt manifestations of psychosis are hallucinations (aberrant sensory experiences), delusions (fixed false beliefs), and ideations (false beliefs not completely fixed). Psychosis may also include less obvious symptoms such as internal preoccupation and illogical/ nonsensical patterns of thinking. Some types of delusions are more characteristic of dementias than primary psychiatric disorders. Psychotic symptoms are more likely in very old patients and appear more frequently in multiinfarct dementia than in Binswanger disease. Therefore, the sudden appearance or exacerbation of psychotic features should prompt a search for a new acute medical condition, such as infection or stroke. In addition, sensory deprivation such as impaired visual acuity or deafness can worsen psychotic symptoms in dementia patients. Psychotic symptoms are usually uncomfortable for patients and/or their caregivers, but the individual nature and circumstances of psychotic symptoms should always be taken into account when considering treatment. For example, if a patient has hallucinations of deceased loved ones but they do not bother him, the most appropriate steps might be education, counselling, and support for a frustrated caregiver. Cholinesterase inhibitors demonstrate modest effectiveness in reducing dementia-related psychotic symptoms. Antidepressant medicines may have some utility as well, with some studies demonstrating equal efficacy with lower side-effects when compared to antipsychotics. The lessons learned from these studies can therefore be applied to both syndrome clusters. Clinicians generally agree that psychotic symptoms are most effectively treated by antipsychotic medications, but benefits and risks can be difficult to balance in demented patients. The pharmacodynamic profiles of antipsychotics also predict potential antiadrenergic, antihistaminic, and anticholinergic side-effects. Importantly, antipsychotics have additional class-specific risks for the elderly and cognitively impaired. Antipsychotic medications are associated with clinically significant increases in shortand long-term rates of cognitive decline, stroke, sudden death, and acute hospitalization. As with all pharmacotherapy, regular assessments of the need for continued medication are necessary. However, it should be noted that relapse rates after discontinuation are high, particularly in patients with severe symptoms. Although an impressive body of data has been accumulated about these symptoms, any clinician with experience in managing internalmedicinebook. Evaluation of three aggression/ agitation behaviour rating scales for use on an acute admission and assessment psychogeriatric ward. Mental and behavioral disturbances in dementia: Findings from the cache county study on memory in aging. Behavioral and psychological symptoms in dementia with Lewy-bodies (dlb): Frequency and relationship with disease severity and motor impairment. Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: A systematic review. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects. Physically violent behaviour in dementia care: Characteristics of residents and management of violent situations. Neuropsychological performance and dementia in depressed patients after 25-year follow-up: A controlled study. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: Prevalence and predictors. Increased attention to neuropsychiatric syndromes, better diagnostic criteria, and improvements in technology will produce a better understanding of their epidemiology, neurobiology, and-most importantly-the best ways to treat them. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: Population-based study. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. Neuropsychiatric symptoms in amnestic mild cognitive impairment: Increased risk and faster progression to dementia. Systematic reviews on behavioural and psychological symptoms in the older or demented population. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Behavioral problems in dementia: A factor analysis of the neuropsychiatric inventory. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: Evidence of compensatory changes.

Apomorphine is a dopamine agonist with efficacy comparable to levodopa gastritis diet watermelon buy 40 mg esomeprazole mastercard, but it must be administered parenterally and has a very short half-life and duration of activity (45 min) gastritis vs gerd order esomeprazole 40 mg with mastercard. It is generally administered by injection as a rescue agent for the treatment of severe "off" episodes gastritis diet 02 purchase genuine esomeprazole line. Apomorphine can also be administered by continuous subcutaneous infusion and has been demonstrated to reduce both "off" time and dyskinesia in advanced patients gastritis diet queen buy 40 mg esomeprazole. Acute side effects are primarily dopaminergic and include nausea chronic gastritis gas proven 40 mg esomeprazole, vomiting, and orthostatic hypotension. Side effects associated with chronic use include hallucinations and cognitive impairment. Sedation with sudden unintended episodes of falling asleep while driving a motor vehicle have been reported. Patients should be informed about this potential problem and should not drive when tired. Dopamine agonists can also be associated with impulse-control disorders, including pathologic gambling, hypersexuality, and compulsive eating and shopping. The precise cause of these problems, and why they appear to occur more frequently with dopamine agonists than levodopa, remains to be resolved, but reward systems associated with dopamine and alterations in the ventral striatum and orbitofrontal regions have been implicated. In general, chronic side effects are dose-related and can be avoided or minimized with lower doses. Injections of apomorphine and patch delivery of rotigotine can be complicated by development of skin lesions at sites of administration. They may increase dyskinesia in levodopa-treated patients, but this can usually be controlled by down-titrating the dose of levodopa. In addition, both selegiline and rasagiline incorporate a propargyl ring within their molecular structure that provides antiapoptotic effects in laboratory models. However, it could not be determined whether this was due to a neuroprotective effect that slowed disease progression or a symptomatic effect that merely masked ongoing neurodegeneration. There is also a combination tablet of levodopa, carbidopa, and entacapone (Stalevo). Severe diarrhea has been described with tolcapone, and to a lesser degree with entacapone, and necessitates stopping the medication in 5­10% of individuals. Cases of fatal hepatic toxicity have been reported with tolcapone, and periodic monitoring of liver function is required. This may have been because the combination was not administered at frequent enough intervals to provide continuous levodopa availability. Their major clinical effect is on tremor, although it is not certain that this benefit is superior to what can be obtained with agents such as levodopa and dopamine agonists. Their use is limited particularly in the elderly, due to their propensity to induce a variety of side effects including urinary dysfunction, glaucoma, and particularly cognitive impairment. However, it is not possible to determine if the positive results were due to neuroprotection with slowing of disease progression or confounding symptomatic effects that mask ongoing progression. CoQ10, a mitochondrial bioenhancer and antioxidant, attracted attention with a positive preliminary trial, but this was not replicated in larger double-blind studies. Lesions placed in the motor cortex improved tremor but were associated with motor deficits, and this approach was abandoned. Importantly, pallidotomy was also associated with marked improvement in contralateral dyskinesia. The stimulation variables can be adjusted with respect to electrode configuration, voltage, frequency, and pulse duration in order to maximize benefit and minimize adverse side effects. In cases with intolerable side effects, stimulation can be stopped and the system removed. The procedure does not require making a lesion in the brain and is thus suitable for performing bilateral procedures with relative safety. It provides dramatic results, particularly with respect to reducing "off" time and dyskinesias, but does not improve or prevent the development of features that fail to respond to levodopa such as freezing, falling, and dementia. The procedure is thus primarily indicated for patients who suffer disability resulting from severe tremor, or levodopa-induced motor complications that cannot be satisfactorily controlled with drug manipulation. Note: Drugs should not be withdrawn abruptly but should be gradually lowered or removed as appropriate. Indeed, it is the only oral agent that has been demonstrated in controlled studies to reduce dyskinesia without worsening parkinsonian features, although benefits may be relatively transient. Amantadine should always be discontinued gradually because patients can experience withdrawal-like symptoms. Several new classes of drug are currently being investigated in an attempt to enhance antiparkinsonian effects, reduce off time, and treat or prevent dyskinesia. A list of the major drugs and available dosage strengths is provided in Table 449-5. These include cell-based therapies (such as transplantation of fetal nigral dopamine cells or dopamine neurons derived from stem cells), gene therapies, and trophic factors. However, two double-blind studies failed to show significant benefit of fetal nigral transplantation in comparison to a sham operation with respect to their primary endpoints. Additionally, grafting of fetal nigral cells is associated with a previously unrecognized form of dyskinesia that persists after lowering or even stopping levodopa. This has been postulated to be related to unregulated release of dopamine from serotonin neurons. Perhaps most importantly, it is not clear how replacing dopamine cells alone will improve nondopaminergic features such as falling and dementia, which are the major sources of disability for patients with advanced disease. Trophic factors are a series of proteins that enhance neuronal growth and restore function to damaged neurons. There are several different trophic factors that have been demonstrated to have beneficial effects on dopamine neurons in laboratory studies. Gene delivery offers the potential of providing widespread delivery throughout a target region and long-term expression of a therapeutic protein with a single procedure. Furthermore, although gene delivery technology has great potential, this approach also carries the risk of unanticipated side 2617 effects, and current approaches directed at the nigrostriatal system do not address the nondopaminergic features of the illness. Some nonmotor features, although not thought to reflect dopaminergic pathology, nonetheless benefit from dopaminergic drugs. For example, problems such as anxiety, panic attacks, depression, sweating, sensory problems, freezing, and constipation all tend to be worse during "off" periods and may improve with better dopaminergic control. Antidepressants should not be withheld, particularly for patients with major depression. Importantly, they can limit the use of dopaminergic agents to obtain satisfactory motor control. Clozapine is the most effective drug, but it can be associated with agranulocytosis, and regular monitoring is required. For this reason, many physicians start with quetiapine even though it has not been established to be effective in placebocontrolled trials. These patients are particularly prone to have hallucinations and diurnal fluctuations. Dopaminergic drugs can worsen cognitive function in demented patients and should be stopped or reduced to try and provide a compromise between antiparkinsonian benefit and preserved cognitive function. Eventually, patients with cognitive impairment should be managed with the lowest dose of standard levodopa that provides meaningful antiparkinsonian effects and does not worsen mental function. Anticholinesterase agents such as rivastigmine and donepezil reduce the rate of deterioration of measures of cognitive function and can improve attention, but do not typically improve cognitive function in any meaningful way. Initial treatment should include adding salt to the diet and elevating the head of the bed to prevent overnight sodium natriuresis. Low doses of fludrocortisone (Florinef) or midodrine provide control for most cases. Mild laxatives or enemas can be useful, but physicians should first ensure that patients are drinking adequate amounts of fluid and consuming a diet rich in bulk with green leafy vegetables and bran. Restless leg syndrome, sleep apnea, and other sleep disorders should be treated as appropriate. Consultation with a sleep specialist and polysomnography may be necessary to identify and optimally treat sleep problems. Dopaminergic therapies can help patients whose gait is worse in "off" time, but there are currently no specific therapies available. Canes and walkers may become necessary to increase stability and reduce the risk of falling. Freezing, where patients suddenly become stuck in place for seconds to minutes as if their feet were glued to the ground, is a major cause of falling. Freezing during "off" periods may respond to dopaminergic therapies, but there are no specific treatments for "on" period freezing. Some patients will respond to sensory cues such as marching in place, singing a song, or stepping over an imaginary line. It is less clear that physical therapy or specific exercises such as tai chi are required. It is important for patients to maintain social and intellectual activities to the extent possible. Education, assistance with financial planning, social services, and attention to home safety are important elements of the overall care plan. Clearly, if an agent could be demonstrated to have disease-modifying effects, it should be initiated at the time of diagnosis. For now, physicians must use their judgment in deciding whether or not to introduce rasagiline (see above) or other drugs for their possible disease-modifying effects. Several studies now suggest that it may be best to start therapy at the time of diagnosis (or soon after) in order to preserve beneficial compensatory mechanisms and possibly provide functional benefits even in the early stage of the disease. In making this decision, the age, degree of disability, and side effect profile of the drug must all be considered. Regardless of initial choice, it is important not to deny patients levodopa when they cannot be adequately controlled with alternative medications. Amantadine is the only drug that has been demonstrated to treat dyskinesia without worsening parkinsonism, but benefits may be short-lasting, and there are important side effects related to cognitive function. Continuous infusion of apomorphine is another treatment option and does not require surgery but is associated with potentially troublesome skin nodules. There are ongoing efforts aimed at developing a long-acting oral or transdermal formulation of levodopa that mirrors the pharmacokinetic properties of a levodopa infusion. Such a formulation might provide all of the benefits of levodopa without motor complications and avoid the need for polypharmacy and surgical intervention. The major hyperkinetic movement disorders and the diseases with which they are associated are considered in this section. It can be most prominent at rest (rest tremor), on assuming a posture (postural tremor), or on actively reaching for a target (kinetic tremor). Tremor is also assessed based on distribution, frequency, and related neurologic dysfunction. Normal individuals can have a physiologic tremor that typically manifests as a mild, high-frequency (10­12 Hz), postural or action tremor that is usually of no clinical consequence and often is only appreciated with an accelerometer. Treatment is initially directed to the control of any underlying disorder and, if necessary, can often be improved with a beta blocker. When the movements are of large amplitude and predominant proximal distribution, the term ballism is used. Sudden, brief (<100 ms), jerk-like, arrhythmic muscle twitches Brief, repeated, stereotyped muscle contractions that can often be suppressed for a short time. These can be simple and involve a single muscle group or complex and affect a range of motor activities. Decision points include: (1) Introduction of a neuroprotective therapy: No drug has been established to have or is currently approved for neuroprotection or disease modification, but there are several agents that have this potential based on laboratory and preliminary clinical studies. Recent studies suggest the early employment of polypharmacy using low doses of multiple drugs to avoid side effects associated with high doses of any one agent. It can present in childhood but dramatically increases in prevalence over the age of 70 years. The tremor is most often manifest as a postural or action (kinetic) tremor and, in severe cases, can interfere with functions such as eating and drinking. It is typically bilateral and symmetric but may begin on one side and remain asymmetric. Tremor involves the head in ~30% of cases, voice in ~20%, tongue in ~20%, face/jaw in ~10%, and lower limbs in ~10%. Subtle impairment of coordination or tandem walking may be present, and disturbances of hearing, cognition, personality, mood, and olfaction have also been described, but usually the neurologic examination is normal aside from tremor. Approximately 50% of cases have a positive family history with an autosomal dominant pattern of inheritance. The cerebellum and inferior olives have been implicated as possible sites of a "tremor pacemaker" based on the presence of cerebellar signs and increased metabolic activity and blood flow in these regions in some patients. Occasionally, tremor can be severe and interfere with eating, writing, and activities of daily living. This is more likely to occur as the patient ages and is often associated with a reduction in tremor frequency. Propranolol (20­120 mg daily, given in 2620 divided doses) is usually effective at relatively low doses, but higher doses may be effective in some patients. Botulinum toxin injections may be helpful for limb or voice tremor, but treatment can be associated with secondary muscle weakness. Dystonia can range from minor contractions in an individual muscle group to severe and disabling involvement of multiple muscle groups. The frequency is estimated to be 300,000 cases in the United States but is likely to be much higher because many cases are not recognized. Dystonia is often brought out by voluntary movements (action dystonia) and can extend to involve muscle groups and body regions not required for a given action (overflow). It can be aggravated by stress and fatigue and attenuated by relaxation and sensory tricks such as touching the affected body part (geste antagoniste).

References

• Rhee P, Brown C, Martin M, et al. QuikClot use in trauma for hemorrhage control: case series of 103 documented uses. J Trauma. 2008;64:1093-1099.
• Merz TM, Etter R, Mende L, et al: Risk assessment in the first fifteen minutes: a prospective cohort study of a simple physiological scoring system in the emergency department. Crit Care 15:R25, 2011.
• Godley CD, Warren RL, Sheridan RL, et al. Nonoperative management of blunt splenic injury in adults: age over 55 years as a powerful indicator for failure. J Am Coll Surg. 1996;183:133-139.
• Wilkinson L, De P, Bloxham C. Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma. J Clin Pathol 2008;61(10):1119-21.
• Saedi MS, Zhu Z, Marker K, et al: Human kallikrein 2 (hK2), but not prostatespecific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells, Int J Cancer 94(4):558n563, 2001.
• Itoh Y, Kojima Y, Yasui T, et al: Examination of alpha 1 adrenoceptor subtypes in the human ureter, Int J Urol 14:749, 2007.